Pulmozyme is a biological agent used to improve lung function in patients with cystic fibrosis. Its shelf life is closely related to storage conditions. Proper storage of drugs can ensure stable efficacy and avoid treatment failure due to deterioration.

Precautions for Pulmozyme(dornase alfa) dornase inhaler

Standard shelf life and packaging integrity

Unopened dornase alfa inhalers have a shelf life of 24 months. Each box contains 2.5mg/2.5mL*30 tubes. The drug must be sealed in the original aluminum foil bag and protected from light and high temperature. Unused single tubes after opening must be refrigerated and used within 24 hours.

Transportation and temporary storage restrictions

The drug must be kept refrigerated at 2°C-8°C throughout the transportation process. If the drug is exposed to a room temperature of 22°C-28°C for more than 60 hours, it must be discarded. When patients receive the medicine, they need to immediately check whether the cold chain packaging is intact. If there is damage or abnormal temperature, they should contact the supplier for replacement.

Clarifying the core influencing factors of the expiration date is the premise for ensuring the activity of the drug. The following content will explain the inspection steps and standard operation methods before use.

Inspection and use of Dornase Alfa(Pulmozyme)

Dornase Alfa(Pulmozyme) needs to be administered through a special nebulizer. Improper operation may affect the absorption efficiency of the drug. Strictly following the usage specifications can maximize the treatment effect.

Drug property inspection and nebulizer selection

Before use, squeeze a single ampoule to check for leakage. If the solution is turbid, discolored or contains particulate matter, it should be discarded immediately. It is recommended to use a jet nebulizer (such as the eRapid system) or a vibrating mesh nebulizer to ensure that the diameter of the nebulized particles is ≤5μm. If pediatric patients cannot cooperate with oral inhalation, they need to use an adaptable mask.

Inhalation operation and cleaning requirements

Inhale a dose of 2.5mg once a day, and it is recommended to operate at a fixed time to form a regularity. The nebulizer needs to be cleaned and disinfected regularly according to the manufacturer's instructions to avoid bacterial contamination. It is strictly forbidden to mix with other drugs for inhalation to prevent physical and chemical reactions. After each use, the parts need to be disassembled, rinsed with sterile water and dried.

Standardized operating procedures are the key to successful treatment. The following content will analyze the metabolic process and mechanism of action of the drug in the body.

Pharmacokinetics of Dornase Alfa(Pulmozyme)

Alpha deoxyribonuclease reduces mucus viscosity by specifically decomposing DNA, and its metabolic characteristics directly affect the frequency of administration and the maintenance of efficacy.

Rapid metabolism and mechanism of action

Intravenous injection studies have shown that the elimination half-life of alpha deoxyribonuclease is 3-4 hours. After inhalation, the drug directly acts on the airway mucus layer, reduces mucus elasticity by hydrolyzing extracellular DNA, and promotes sputum discharge. Once-daily administration can maintain effective drug concentrations and continuously improve lung function.

No significant drug interactions

Current clinical data show that alpha deoxyribonuclease has no metabolic conflicts with other drugs (such as antibiotics and bronchodilators) and can be used safely in combination. There is no need to adjust the dose of other drugs during treatment, but local irritation reactions of combined medications still need to be monitored.

Following the doctor's advice and regularly evaluating lung function indicators (such as FVC) can help optimize the treatment effect. Patients need to properly store the drugs to avoid repeated freezing and thawing or high temperature exposure. If the performance of the nebulizer is found to be degraded or the drug properties are abnormal, the equipment should be replaced in time or the pharmacist should be consulted. Through scientific management and standardized operation, Dornase Alfaa can significantly improve the quality of life of patients with cystic fibrosis.